Differential effects of extracellular vesicles secreted by mesenchymal stem cells from different sources on glioblastoma cells
A Del Fattore, R Luciano, R Saracino… - Expert opinion on …, 2015 - Taylor & Francis
Background: Malignant glial tumors, including glioblastoma multiforme, account for 15–20%
of pediatric CNS malignancies. They are most resistant to therapy and are associated with a …
of pediatric CNS malignancies. They are most resistant to therapy and are associated with a …
Experimental approaches for the treatment of malignant gliomas
Malignant gliomas, which include glioblastomas and anaplastic astrocytomas, are the most
common primary tumors of the brain. Over the past 30years, the standard treatment for these …
common primary tumors of the brain. Over the past 30years, the standard treatment for these …
Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition
PA Clark, M Iida, DM Treisman, H Kalluri, S Ezhilan… - Neoplasia, 2012 - Elsevier
Epidermal growth factor receptor (EGFR) signaling is strongly implicated in glioblastoma
(GBM) tumorigenesis. However, molecular agents targeting EGFR have demonstrated …
(GBM) tumorigenesis. However, molecular agents targeting EGFR have demonstrated …
MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis
Y Cheng, Y Zhang, L Zhang, X Ren… - Molecular cancer …, 2012 - AACR
Gefitinib, a small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase,
has been shown to induce autophagy as well as apoptosis in tumor cells. Yet, how to use …
has been shown to induce autophagy as well as apoptosis in tumor cells. Yet, how to use …
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study
SG DuBois, S Shusterman, AM Ingle, CH Ahern… - Clinical Cancer …, 2011 - AACR
Purpose: Sunitinib is an oral multitargeted receptor tyrosine kinase inhibitor. The purpose of
this study was to determine the recommended phase 2 dose, pharmacokinetics …
this study was to determine the recommended phase 2 dose, pharmacokinetics …
Bimodal therapeutic agents against glioblastoma, one of the most lethal forms of cancer
M Couto, C Alamón, S Nievas, M Perona… - … A European Journal, 2020 - Wiley Online Library
About 95% of people diagnosed with glioblastoma die within five years. Glioblastoma is the
most aggressive central nervous system tumour. It is necessary to make progress in the …
most aggressive central nervous system tumour. It is necessary to make progress in the …
Sunitinib-containing carborane pharmacophore with the ability to inhibit tyrosine kinases receptors FLT3, KIT and PDGFR-β, exhibits powerful in vivo anti-glioblastoma …
Simple Summary Glioblastoma is one of the most aggressive central nervous system tumors.
Combinations of therapies, such as tyrosine kinase receptor inhibition and boron neutron …
Combinations of therapies, such as tyrosine kinase receptor inhibition and boron neutron …
In vitro and in vivo analysis of RTK inhibitor efficacy and identification of its novel targets in glioblastomas
O Martinho, R Silva-Oliveira, V Miranda-Goncalves… - Translational …, 2013 - Elsevier
Abstract Treatment for glioblastoma consists of radiotherapy and temozolomide-based
chemotherapy. However, virtually all patients recur, leading to a fatal outcome. Receptor …
chemotherapy. However, virtually all patients recur, leading to a fatal outcome. Receptor …
Incorporation of lapatinib into core–shell nanoparticles improves both the solubility and anti-glioma effects of the drug
Purpose Lapatinib is a dual EGFR and HER2 inhibitor that is used to treat HER2-
overexpressing cancers. However, its poor water solubility hinders its clinical use …
overexpressing cancers. However, its poor water solubility hinders its clinical use …
Recent advances in targeted therapy for glioblastoma
Glioblastomas are the most common form of brain tumor with a very dismal prognosis. While
a standard treatment regimen of surgery followed by chemo/radiotherapy is currently used …
a standard treatment regimen of surgery followed by chemo/radiotherapy is currently used …